Gates Interview

When asked how he would explain Alzheimer’s research to a younger person, Dr. Bose started with how the disease was first understood.
 

“Alzheimer’s disease was named after Dr. Alois Alzheimer, who noticed in an autopsy that certain parts of the brain had shrunk. For a long time, the disease was only recognized after that kind of pathology was seen.”
 

Today, researchers define Alzheimer’s in part by the buildup of a protein called amyloid, which forms clumps known as plaques in the brain.
 

“Now we know that the deposition of a protein called amyloid, which forms aggregates or plaques, is what defines whether someone is labeled as having Alzheimer’s disease.”
 

But having those plaques does not always mean having symptoms.
 

“In most diseases, when we say somebody has an illness, they have symptoms. In Alzheimer’s, people can be labeled as having the disease even when many of them don’t have symptoms, because it’s the protein accumulation that defines it.”
 

Some people live with a great deal of amyloid in their brains and remain cognitively normal. Others have relatively little amyloid but decline quickly. That mismatch points to the biggest open question in the field.
 

“The biggest unmet need in the field is the big picture question: why are some people resilient, and why are some people fast progressors?”
 

Researchers still don’t fully understand what causes amyloid to build up in the first place, or what happens next as another protein, tau, forms tangles and spreads through the brain.
 

“We don’t understand the biological pathway completely. Why does amyloid accumulate? And once it accumulates, what happens?We think tau is downstream of amyloid. Once tau is seeded and starts forming tangles, it becomes very difficult to change the course.”
 

That uncertainty opens into a set of very human questions.
 

“Why do women get more Alzheimer’s than men? Is there a trigger at menopause that actually drives women down the path of increased incidence of Alzheimer’s disease? There are lots of unanswered questions.”
 

Factors like sleep and the immune system may also play a role in who develops Alzheimer’s and how quickly it progresses. As Dr. Bose put it, “There are lots of unanswered questions.” That distinction—between having Alzheimer’s pathology and having symptoms—changes how progress in the field should be understood. It’s not only about clearing amyloid. It’s about figuring out why some brains cope and others don’t.
​
 

Despite these gaps, the last decade has brought real advances. Dr. Bose highlighted three major shifts.
 

The first is diagnostic: blood tests that detect amyloid in the brain.
 

“We now have blood tests that can very accurately indicate whether an individual has amyloid in their brain. In many cases, they can definitively say yes or no; in some cases, further imaging is still needed. It’s a phenomenal advance, not just for diagnosing people, but also for enrolling them in clinical trials.”
 

Instead of requiring PET scans, MRIs, or spinal taps, a simple blood draw can indicate whether amyloid is present. That lowers the barrier to diagnosis and makes it easier to recruit participants for studies.
 

The second shift is treatment. Two antibody therapies have now been approved for early-stage Alzheimer’s.
 

“They don’t bring as much treatment effectiveness as we would have liked. These are infusions, but they’re now being modified into subcutaneous self-administration pens. That gives hope to the field.”
 

For someone who might decline over three years, these treatments can buy extra time—“a fourth year,” as Dr. Bose described it, of a cognitively healthier life. Trials are now testing whether clearing amyloid earlier can delay or prevent symptoms altogether.
 

Even with better diagnostics and treatments, access remains a major gap.
 

“The treatments aren’t being reimbursed, the diagnostics aren’t widely available. Access is a big challenge for all of them.”
 

And then there’s the human side: what happens after someone is told they have mild cognitive impairment or early Alzheimer’s?
 

“Even when somebody gets diagnosed or is told they have memory loss, what should they do next? Where do they go for resources, for expert advice, for information about clinical trials? We need to do a better job as a system, as a country, of helping define that pathway.”

For organizations focused on awareness and support, that “what now?” question is where much of their work begins.

​​
 

​

Underneath the diagnostics and treatments is a deeper layer: understanding Alzheimer’s as a spectrum of diseases, not a single condition.
 

“I don’t believe Alzheimer’s is one disease. I think it’s a spectrum of multiple diseases that come together, maybe with one common outcome, which is amyloid accumulation. There could be five or six different ways people end up accumulating amyloid.”
 

To untangle those subtypes, researchers rely on biomarkers: proteins, genomic transcripts, and other signals that change as the disease progresses.
 

“If you want to understand the research pathways that cause disease, you need to do biomarker analysis: which proteins go up, which come down, which genomic transcripts change, and so on.”
 

But biomarkers alone aren’t enough. The data behind them has to be shared. Dr. Bose pointed to the Framingham Heart Study, a long-term study in Massachusetts that has followed families for three generations.
 

“What started as a heart study is now a hugely valuable data set for cognition, aging, and memory loss. If we don’t make that data set available to researchers who are studying memory loss and cognitive decline, it’s a crime.”
 

Participants enrolled to contribute to science, not just to study heart disease. With proper privacy and consent, reusing existing data can help answer questions that no new study could tackle alone: why some people decline faster, why some stay cognitively normal into their 90s, why women are affected more than men.
 

“We shouldn’t need new studies for all of these questions. The data is already there. You can’t prove anything if it isn’t there. So analyze the data.”
 

This is where philanthropy plays a specific role, and Dr. Bose was clear that the role changes depending on the field. He contrasted Alzheimer’s with malaria, where there’s no rich-world market driving investment, so philanthropy has to carry nearly the whole load. Alzheimer’s is different: it draws roughly four billion dollars a year in NIH funding alone, plus real interest from biotech and big pharma, given the size of the market across the U.S., Western Europe, Japan, and Australia. That changes what philanthropy’s job actually is.
 

“The rules of philanthropy have to be: high risk, opportunistic, catalytic, and quick. If we take the same amount of time to review grants that NIH does, then we’re not bringing value as a philanthropy. Philanthropy’s role has to be about seeding, de-risking, proving a concept, and then enabling progress. Philanthropy cannot sustain things in perpetuity.”
 

He described the Diagnostics Accelerator, a philanthropic fund created in 2017 when blood-based Alzheimer’s diagnostics had no clear market.
 

“We came together as philanthropies to set up something called the Diagnostics Accelerator. We funded only diagnostic companies, mostly blood-based tests. If those companies were successful, the foundation would get a small return and put it back into the fund. Now we have a robust diagnostic pipeline. I think our role there is done.”
 

Once the market exists, philanthropy can move on to the next unmet need.
 

Every dataset, like every story, carries more questions than the people who collected it originally imagined. A senior’s interview isn’t just a record of their past. It becomes part of a larger picture about aging, community, and memory.
 

​

Community work and research advocacy might seem far apart, but in Alzheimer’s, they’re tightly connected. Grassroots movements help shape policy and funding, from state budgets to federal bills like the ASAP Act. Events like the Walk to End Alzheimer’s raise money that funds early-career investigators and fellowships, bringing new talent into the field.

“You need ideas from all disciplines to be able to solve a problem like Alzheimer’s disease.”

Storytelling sits at the intersection of community, cognition, and connection. One of the most painful aspects of memory loss and aging is loneliness.
 

“One of the common pitfalls of memory loss and aging is loneliness and isolation. It’s a vicious cycle. Hearing loss leads to loneliness, and then people don’t exercise their brain because they’re not communicating. There is also a bit of stigma in the community when somebody has memory loss, so people don’t engage them. And they decline.”

Staying mentally and socially active isn’t just “nice to have.” It’s part of what the evidence supports. Dr. Bose pointed to lifestyle-intervention studies like FINGER (in Finland) and POINTER (in the U.S.), which combine diet, exercise, cognitive training, and social engagement.
 

“For two years, when they followed people who did these combined lifestyle interventions, they found a significant reduction in cognitive decline and, in some analyses, a lower risk of dementia. It is indeed feasible to actually delay it, unless there’s a strong genetic predisposition. Most Alzheimer’s is not predisposed. It’s what we call sporadic, late-onset.”

In that context, storytelling isn’t a side project. It’s a form of cognitive stimulation and community-building.

“That’s where storytelling comes in. People are remembering things from their past, connecting dots for themselves and for others. I think it triggers a lot of cognitive pruning, so to speak. It’s that fabric pulling the community together. That’s immensely helpful.”

We’ve heard seniors say, “My life isn’t interesting,” after decades of work, family, and survival. Hearing Dr. Bose describe storytelling as a form of cognitive stimulation—and community as a protective factor—made that statement feel even more urgent. Preserving these stories isn’t just about memory. It’s about keeping people connected, seen, and mentally active.

 

At Storykeepers, each interview becomes a two-page spread in a printed town chapter. We distribute those books to every participating senior, to their senior centers, and to local libraries so anyone in town can read them. The goal isn’t just to archive stories, but to put them back into the hands of the community.

 

Alongside this, we partner with the Alzheimer’s Association to raise awareness and support events like the Walk to End Alzheimer’s in our area, connecting local storytelling work to a broader movement.

​


 

The conversation ended where it began: with a simple question about what matters most in Alzheimer’s research. The answer wasn’t only blood tests, biomarkers, or funding. It was people: how they live, connect, and remember.
 

If storytelling is part of the solution, then every senior who sits down to share their life isn’t just recounting the past. They’re helping shape what memory care might look like in the future.